Centre for Probe Development and Commercialization   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Hamilton OH United States (2008)

Organization Overview

First Clinical Trial
2013
NCT01738347
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Centre for Probe Development and Commercialization

Active Ingredients

Drugs in Phase 2 Trials (1)

piflufolastat (PYLARIFY) (1 trial)

Drugs in Phase 1 Trials (3)

cpd-1028 (1 trial)

cpd-1061 (1 trial)

geh120714 (1 trial)

Drugs in Other Trials (1)

99mtc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Prostatic Neoplasms (Phase 2)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 5